BlackRock Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

BlackRock Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.25M	Sell	37,209 -7,255	-16%	-$208K	﹤0.01%	1742
2016 Q3	$1.18M	Sell	44,464 -993	-2%	-$23.1K	﹤0.01%	1735
2016 Q2	$1M	Sell	45,457 -5,062	-10%	-$132K	﹤0.01%	1766
2016 Q1	$1.48M	Buy	50,519 +5,407	+12%	+$151K	﹤0.01%	1567
2015 Q4	$1.49M	Sell	45,112 -8,246	-15%	-$269K	﹤0.01%	1530
2015 Q3	$1.93M	Sell	53,358 -2,393	-4%	-$103K	﹤0.01%	1374
2015 Q2	$2.51M	Sell	55,751 -29,353	-34%	-$1.14M	﹤0.01%	1181
2015 Q1	$2.61M	Buy	85,104 +27,518	+48%	+$1.07M	﹤0.01%	1132
2014 Q4	$2.93M	Sell	57,586 -12,644	-18%	-$566K	﹤0.01%	1089
2014 Q3	$2.78M	Buy	70,230 +28,226	+67%	+$1.13M	﹤0.01%	1093
2014 Q2	$1.81M	Buy	42,004 +40,051	+2,051%	+$1.53M	﹤0.01%	1202
2014 Q1	$78K	Buy	1,953 +59	+3%	+$2.14K	﹤0.01%	3132
2013 Q4	$52K	Sell	1,894 -79	-4%	-$1.92K	﹤0.01%	3232
2013 Q3	$45K	Sell	1,973 -42,025	-96%	-$803K	﹤0.01%	3213
2013 Q2	$779K	Buy	+43,998	New	+$858K	﹤0.01%	1521

Other funds holding ENTA

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Advisors's ENTA Position: Q4 2016 in Review

BlackRock Advisors reduced its Enanta Pharmaceuticals (ENTA) stake by 16% in Q4 2016, selling an estimated $208K and leaving 37,209 shares worth $1.25M. The position accounts for ﹤0.01% of the portfolio, ranked #1742.

BlackRock Advisors first reported a position in ENTA in Q2 2013 and has held it in 15 quarters since. The position peaked at $2.93M in Q4 2014. 149 funds tracked by Wall St. Rank hold ENTA as of Q4 2016.

BlackRock Advisors held 37,209 shares of Enanta Pharmaceuticals worth $1.25M as of Q4 2016.
BlackRock Advisors sold 7,255 Enanta Pharmaceuticals shares in Q4 2016, an estimated $208K.
Enanta Pharmaceuticals made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #1742 holding.
BlackRock Advisors first reported a position in Enanta Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
BlackRock Advisors's Enanta Pharmaceuticals position peaked at $2.93M in Q4 2014.
149 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.